Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy

Clin Nucl Med. 2016 Dec;41(12):951-952. doi: 10.1097/RLU.0000000000001374.

Abstract

A 66-year-old man with castration-resistant prostate carcinoma and multiple symptomatic bone mestastases was considered for Ra-dichloride (Xofigo) therapy. Staging with Ga-PSMA-PET/CT revealed additional extensive tumor involvement of the spine without relevant uptake in bone scintigraphy. Based on this imaging result, the patient was rescheduled for a PSMA-targeted therapy. Additional Ga-PSMA-PET/CT may have a considerable benefit for patients considered for Xofigo.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Carcinoma / diagnostic imaging*
  • Carcinoma / radiotherapy
  • Edetic Acid / analogs & derivatives
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Humans
  • Male
  • Oligopeptides
  • Organometallic Compounds
  • Positron Emission Tomography Computed Tomography*
  • Prostatic Neoplasms, Castration-Resistant / diagnostic imaging*
  • Prostatic Neoplasms, Castration-Resistant / radiotherapy
  • Radioisotopes / therapeutic use
  • Radiopharmaceuticals / therapeutic use
  • Radium / therapeutic use

Substances

  • Gallium Isotopes
  • Gallium Radioisotopes
  • Oligopeptides
  • Organometallic Compounds
  • Radioisotopes
  • Radiopharmaceuticals
  • gallium 68 PSMA-11
  • Edetic Acid
  • radium Ra 223 dichloride
  • Radium